Table 2.

Safety analysis of α1-adrenergic receptor blockers

	Alfuzosin (n = 2475)			Tamsulosin (n = 3004)			Terazosin (n = 3701)			Doxazosin (n = 2249)			Doxazosin GITS (n = 686)
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Dizziness	1.49	1.02, 2.17	0.040	1.35	0.97, 1.88	0.075	3.06	2.22, 4.20	< 0.0001	2.890	1.804, 4.631	< 0.0001	4.196	1.748, 10.074	0.001
Hypotension	2.44	0.86, 6.79	0.095	1.13	0.17, 7.54	0.897	5.36	2.61, 11.00	< 0.0001	2.525	1.578, 4.041	< 0.0001	2.608	0.706, 9.630	0.150
Headache	1.38	0.83, 2.29	0.209	0.97	0.72, 1.30	0.834	1.07	0.65, 1.75	0.800	0.992	0.500, 1.967	0.982	1.456	0.683, 3.100	0.330
Asthenia/fatigue	1.42	0.79, 2.57	0.240	1.38	0.87, 2.19	0.170	2.42	1.79, 3.28	< 0.0001	2.434	1.861, 3.184	< 0.0001	3.168	0.908, 11.049	0.071
Syncope	2.62	0.61, 11.32	0.196	0.77	0.16, 3.73	0.740	1.96	0.41, 9.37	0.400	1.963	0.177, 21.781	0.985	–
Dizziness, hypotensionor syncope	1.66	1.17, 2.36	0.005	1.42	0.99, 2.05	0.053	3.71	2.48, 5.53	< 0.0001	3.320	2.100, 5.230	< 0.0001	3.860	1.860, 8.020	< 0.0001

CI, confidence interval; OR, odds ratio; GITS, gastrointestinal therapeutic system. Bold values indicate statistical significance relative to placebo.